Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Pacific Edge Limited ( (PFGTF) ) is now available.
Pacific Edge Limited has announced the appointment of Simon Flood as Director and Chairman Designate, succeeding Chris Gallaher. Flood brings extensive experience in business leadership and capital markets, which is expected to benefit the company as it seeks to regain Medicare reimbursement for its Cxbladder tests in the US. The inclusion of Cxbladder Triage in the American Urological Association’s guidelines is seen as a positive step towards influencing healthcare payer policies. The transition in leadership comes at a critical time as the company prepares for a review by Medicare’s Administrative Contractor, potentially leading to revised coverage determinations.
More about Pacific Edge Limited
Pacific Edge Limited is a global cancer diagnostics company specializing in the development and commercialization of bladder cancer diagnostic and prognostic tests. Headquartered in Dunedin, New Zealand, the company offers its Cxbladder suite of non-invasive genomic urine tests for patients with hematuria or recurrent disease surveillance. These tests are available globally, including in the US, Australasia, Israel, and various markets in Asia and South America.
Learn more about PFGTF stock on TipRanks’ Stock Analysis page.